Loading
Daxor Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Apr 2026.
Daxor Corp: what insiders have been doing
Daxor Corp belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 4 insiders published 10 filings.
Only purchases show up on the open market, 6 purchases in all worth €16k, filed by 4 insiders. The amount is not disclosed for 4 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a purchase of €8,554 from Michel Robert J, disclosed on 31 March 2026. Among those who bought: 2 senior executives, 1 finance chief and 1 chief executive.
Within a 30-day window, 1 purchase overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 10 April 2026, which is 191 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 10 filings here. The full history, which starts in 2021, counts 27 purchases against no sales.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
35
Thresholds
n/a
Buy Volume
€175,820
27 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleMichael Richard Feldschuh4 buys
Robert J. Michel3 buys
John Jefferies2 buys
Jonathan Adam Feldschuh2 buys
Since the insiders bought
- +11.7%Entry US$9.43 · Close at T+90 US$10.53
- +6.9%Entry US$9.63 · Close at T+90 US$10.29
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,175 of 24,161 companies
78.9
score / 100
Value70
Quality88
FCF yld1.0%
Earn yld16%
EV/EBITDA·
ROE14%
Gross mgn·
Net mgn89%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$10.09
Analyst consensus
2 analysts1.50/5
US$18.00Target US$20.00(+98%)US$22.00
Income statement
RevenueUS$10.3M
Net incomeUS$9.2M19861.4% margin
Valuation
PER (trailing)9.4x
P/Book1.1x
Beta0.35
Balance sheet & cash
Market capUS$58.9M
Total debtUS$730k
Free Cash FlowUS$570.9k
Profitability & ownership
ROE14.2%
ROA-2.6%
% insiders49.5%
% institutions7.0%
Last declaration on 1 September 2026
Declarations35 total
2,451 shares0Daxor Common StockSEC:0001493152-26-040999:0
25,000 sharesDaxor Common StockSEC:0001493152-26-030187:0
30,000 sharesDaxor Common StockSEC:0001493152-26-030192:0
12,000 sharesDaxor Common StockSEC:0001493152-26-030197:0
1,000 shares@ US$9.0710.6% of flowDaxor Common StockSEC:0001493152-26-016105:0
Canonical exit: 7 Jul 2026 (T+90)
1,000 shares@ US$9.9020.5% of flowDaxor Common StockSEC:0001493152-26-014397:0
Canonical exit: 29 Jun 2026 (T+90)
3,656 shares0Daxor Common StockSEC:0001493152-26-012444:0
Canonical exit: 18 Jun 2026 (T+90)
3,000 shares0Daxor Common StockSEC:0001493152-25-027230:0
Canonical exit: 9 Mar 2026 (T+90)
18,000 shares0Daxor Common StockSEC:0001493152-25-027228:0
Canonical exit: 9 Mar 2026 (T+90)
2,344 shares0Daxor Common StockSEC:0001493152-25-023651:0
Canonical exit: 10 Feb 2026 (T+90)
2,063 shares@ US$7.8920.0% of flowDaxor Common StockSEC:0001641172-25-002969:0
Canonical exit: 3 Jul 2025 (T+90)
1,000 shares@ US$8.138.5% of flowDaxor Common StockSEC:0001641172-25-000881:0
Canonical exit: 24 Jun 2024 (T+90)
1,492 shares@ US$7.7211.9% of flowDaxor Common StockSEC:0001641172-25-000078:0
Canonical exit: 8 Jun 2024 (T+90)
647 shares@ US$8.155.5% of flowDaxor Common StockSEC:0001641172-25-000076:0
Canonical exit: 17 Jun 2024 (T+90)
3,360 shares@ US$7.6832.3% of flowDaxor Common StockSEC:0001493152-25-009799:0
Canonical exit: 8 Jun 2025 (T+90)
1,000 shares@ US$8.0017.7% of flowDaxor Common StockSEC:0001493152-25-009800:0
Canonical exit: 8 Jun 2025 (T+90)
32,000 shares0Daxor Common StockSEC:0001493152-24-049531:0
Canonical exit: 6 Mar 2025 (T+90)
45,000 shares0Daxor Common StockSEC:0001493152-24-049529:0
Canonical exit: 6 Mar 2025 (T+90)
4,750 shares0Daxor Common StockSEC:0001493152-24-049527:0
Canonical exit: 25 Jun 2023 (T+90)
750 shares@ US$8.7014.5% of flowDaxor Common StockSEC:0001493152-24-011454:0
Canonical exit: 25 Jun 2024 (T+90)
1,000 shares@ US$7.21100.0% of flowDaxor Common StockSEC:0001493152-24-009031:0
Canonical exit: 2 Jun 2024 (T+90)
120 shares@ US$7.752.1% of flowDaxor Common StockSEC:0001493152-23-043860:0
Canonical exit: 5 Mar 2024 (T+90)
180 shares@ US$7.753.1% of flowDaxor Common StockSEC:0001493152-23-043472:0
Canonical exit: 29 Feb 2024 (T+90)
800 shares@ US$7.807.8% of flowDaxor Common StockSEC:0001493152-23-043469:0
Canonical exit: 29 Feb 2024 (T+90)
500 shares@ US$7.948.7% of flowDaxor Common StockSEC:0001493152-23-042692:0
Canonical exit: 22 Feb 2024 (T+90)
25 of 35 declarations
About Daxor Corp
Daxor Corporation (ticker DXR) is a U.S.-listed micro-cap on the Nasdaq Capital Market in the United States, and it operates in a highly specialized segment of healthcare: objective blood volume measurement. For francophone investors, Daxor is best understood as a diagnostic medtech company rather than a conventional pharmaceutical business. Its core mission is to improve clinical decision-making by providing rapid, quantitative, and reproducible assessment of a patient’s blood volume status, particularly in cardiology, intensive care, sepsis, dialysis, surgery, and trauma settings. ([daxor.com](https://daxor.com/company-overview/?utm_source=openai))
The company presents a long operating history, stating that it has roughly 50 years of experience developing and commercializing its Blood Volume Analysis (BVA) technology. Daxor’s operational headquarters are in Oak Ridge, Tennessee, where it also runs a U.S.-based 20,000-square-foot manufacturing facility. That domestic footprint is strategically important in medical devices, where regulatory compliance, manufacturing quality, and hospital customer proximity matter materially. ([daxor.com](https://daxor.com/company-overview/?utm_source=openai))
Read moreShow less
At the center of the business is Daxor’s proprietary, patented, FDA-cleared diagnostic platform, the Blood Volume Analyzer. The company describes it as the only FDA-cleared diagnostic test that directly quantifies total blood volume, plasma volume, and red cell volume. Management positions the product as a way to replace subjective fluid-management guesswork with objective patient-specific data, aiming to improve outcomes and reduce costly complications. In recent communications, Daxor has emphasized a new-generation analyzer that is faster, more compact, and portable, designed to ease adoption across a broader range of clinical environments. ([daxor.com](https://daxor.com/daxor-corporation-receives-fda-clearance-for-new-rapid-lightweight-blood-volume-analysis-system/?utm_source=openai))
From a competitive standpoint, Daxor occupies a narrow but differentiated niche. Its investment case rests on clinical objectivity, intellectual-property protection, regulatory validation, and the economic value of better fluid management in high-acuity care. In 2026, the company highlighted stronger operating momentum in fiscal 2025, including growth in operating revenue, while also signaling a strategic refocus on its core diagnostic business. It further announced plans to transition its primary reporting framework from the Investment Company Act of 1940 to the Securities Exchange Act of 1934, which the market may interpret as another sign of business maturation and a stronger emphasis on the operating platform. ([daxor.com](https://daxor.com/daxor-corporation-reports-2025-fiscal-year-results-operating-revenue-up-45-net-asset-value-rises-to-9-07-per-share/?utm_source=openai))
A key recent milestone was FDA 510(k) clearance in August 2025 for the next-generation rapid, lightweight Blood Volume Analyzer. Daxor then expanded its commercial and scientific visibility with appearances at major 2026 medical conferences, including SCCM and ACC.26. For investors, these events suggest a company trying to convert regulatory progress into broader clinical adoption, stronger hospital penetration, and increased recognition in critical care and cardiology markets. ([daxor.com](https://daxor.com/daxor-corporation-receives-fda-clearance-for-new-rapid-lightweight-blood-volume-analysis-system/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
